May 15, 2020 / 12:41 PM / 22 days ago

BRIEF-Outlook Therapeutics Reports Q2 Loss Per Share $0.36

May 15 (Reuters) - Outlook Therapeutics Inc:

* OUTLOOK THERAPEUTICS REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER OF FISCAL YEAR 2020 AND PROVIDES CORPORATE UPDATE

* Q2 LOSS PER SHARE $0.36

* ENROLLMENT IN NORSE 2 REGISTRATION CLINICAL TRIAL REMAINS ONGOING AND IS EXPECTED TO BE COMPLETED IN CALENDAR Q3 2020

* OUTLOOK THERAPEUTICS - ON TRACK TO REPORT TOPLINE DATA RESULTS FROM NORSE 1, FIRST REGISTRATION CLINICAL TRIAL EVALUATING ONS-5010 IN AUGUST 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below